A direct comparison between lornoxicam and the first marketed specific COX-2 inhibitor in Germany, rofecoxib, with respect to efficacy and tolerability has not yet been performed. The results of ...
Subjects (n = 32 for both studies) were to receive 1 week's treatment with esomeprazole 40mg once daily (studies A and B), naproxen 250mg twice daily (study A), rofecoxib 12.5mg once daily (study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback